Olympus introduces new Enzymatic Creatinine assay

Olympus has announced the introduction of its new Enzymatic Creatinine assay, suitable for use across the range of Olympus diagnostic analysers. It is intended for use for quantitative determination of creatinine in human serum, plasma and urine. The new assay utilises an enzymatic method to achieve greater accuracy, showing less interference to bilirubin and antibiotics.

The new Olympus assay compliments the current Jaffe method, providing increased accuracy of creatinine measurements for specific patients where potential interferents exists from diabetics, renal failure, liver failure and jaundice specimens.

With a very broad measuring range, the new Olympus enzymatic assay is extremely precise and accurate, demonstrating excellent agreement with the GC/MS reference method. The limit of detection for creatinine using serum settings on an Olympus AU640 analyser was established at 0.88µmol/L. This assay clearly meets the NKDEP guidelines and will minimise errors in eGFR calculations.

The new assay employs the same calibrators and controls as the current Jaffe method, however, to ensure optimal traceability, new set-points for calibrator and target values, as well as ranges for control sera have been assigned. Sold in a kit format, the reagent has improved on board stability of 60 days and a calibration stability of 14 days for serum and 30 days for urine.

Creatinine measurement is the most commonly used indicator of renal function and has proved useful in monitoring patients with renal failure and those undergoing renal dialysis.